Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke
NCT ID: NCT00075959
Last Updated: 2013-01-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
600 participants
INTERVENTIONAL
2004-08-31
2006-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke
NCT00061022
Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke
NCT00119626
Efficacy and Safety of Minocycline in the Treatment of Intracerebral Hemorrhage
NCT07305896
Evaluation of CN-105 in Subject With Acute Supratentorial Intracerebral Hemorrhage
NCT03711903
Tranexamic Acid for Acute ICH Growth prEdicted by Spot Sign
NCT02625948
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NXY-059
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Intracerebral Hemorrhage as the cause of stroke symptoms
* Onset of symptoms within 6 hours
* Full functional independence prior to the present stroke
Exclusion Criteria
* Subjects who are unlikely to complete the infusion of investigational product and/or are unlikely to undergo active medical management during that period due to a severe clinical condition.
* Severe illness with life expectancy less than 6 months.
* Known severe kidney disorder.
* Current known alcohol or illicit drug abuse or dependence.
* Pregnant or breast-feeding.
* Treatment with acetazolamide and methotrexate is not permitted during the infusion
* Participation in a previous clinical study within 7 days.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
AstraZeneca NXY-059 Medical Science Director, MD
Role: STUDY_DIRECTOR
AstraZeneca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Birmingham, Alabama, United States
Research Site
Scottsdale, Arizona, United States
Research Site
Fort Smith, Arkansas, United States
Research Site
Carmichael, California, United States
Research Site
Sacramento, California, United States
Research Site
San Diego, California, United States
Research Site
San Jose, California, United States
Research Site
Santa Rosa, California, United States
Research Site
Walnut Creek, California, United States
Research Site
Danbury, Connecticut, United States
Research Site
Melbourne, Florida, United States
Research Site
Ocala, Florida, United States
Research Site
Pompano Beach, Florida, United States
Research Site
Port Charlotte, Florida, United States
Research Site
Punta Gorda, Florida, United States
Research Site
Tampa, Florida, United States
Research Site
Weston, Florida, United States
Research Site
Atlanta, Georgia, United States
Research Site
Decatur, Georgia, United States
Research Site
Duluth, Georgia, United States
Research Site
Lawrenceville, Georgia, United States
Research Site
Honolulu, Hawaii, United States
Research Site
Arlington Heights, Illinois, United States
Research Site
Maywood, Illinois, United States
Research Site
Fort Wayne, Indiana, United States
Research Site
Des Moines, Iowa, United States
Research Site
Louisville, Kentucky, United States
Research Site
Marrero, Louisiana, United States
Research Site
Shreveport, Louisiana, United States
Research Site
South Weymouth, Massachusetts, United States
Research Site
Worcester, Massachusetts, United States
Research Site
Ann Arbor, Michigan, United States
Research Site
East Lansing, Michigan, United States
Research Site
Robbinsdale, Minnesota, United States
Research Site
Kansas City, Missouri, United States
Research Site
Omaha, Nebraska, United States
Research Site
Reno, Nevada, United States
Research Site
Edison, New Jersey, United States
Research Site
Holmdel, New Jersey, United States
Research Site
Morristown, New Jersey, United States
Research Site
Ridgewood, New Jersey, United States
Research Site
Summit, New Jersey, United States
Research Site
Manhasset, New York, United States
Research Site
Schenectady, New York, United States
Research Site
Durham, North Carolina, United States
Research Site
Winston-Salem, North Carolina, United States
Research Site
Akron, Ohio, United States
Research Site
Cleveland, Ohio, United States
Research Site
Toledo, Ohio, United States
Research Site
Youngstown, Ohio, United States
Research Site
Oklahoma City, Oklahoma, United States
Research Site
Abington, Pennsylvania, United States
Research Site
Danville, Pennsylvania, United States
Research Site
Hershey, Pennsylvania, United States
Research Site
Philadelphia, Pennsylvania, United States
Research Site
Pittsburgh, Pennsylvania, United States
Research Site
Bristol, Tennessee, United States
Research Site
Memphis, Tennessee, United States
Research Site
Houston, Texas, United States
Research Site
Lubbock, Texas, United States
Research Site
Virginia Beach, Virginia, United States
Research Site
Olympia, Washington, United States
Research Site
Madison, Wisconsin, United States
Research Site
Marshfield, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0012
Identifier Type: -
Identifier Source: secondary_id
CHANT
Identifier Type: -
Identifier Source: secondary_id
SA-NXY-0012
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.